Side-by-side · Research reference

SelankvsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft11/40 cited

BFDA-ApprovedVerified15/53 cited

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Selank

Semaglutide

Primary target

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

No GABA-receptor binding; no dependence reportedMedvedev 2007

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

Selank

Semaglutide

Standard dose

150–300 mcg / dose intranasalZaderej 2014

—

Frequency

2–3× per day during stress

Once weekly, same day each week

Lower / starter dose

75 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinical trialsMedvedev 2007

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Duration

10–14 day cycles, repeated as needed

Indefinite for chronic indication

Discontinuation results in weight regain.

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

Morning + early afternoon preferred

Any time of day, with or without food

Half-life

Short (minutes plasma); CNS effect lasts ~3 hr

~7 days (168 h)WEGOVY (semaglutide) injection 2021

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

04Side Effects & Safety

Parameter

Selank

Semaglutide

Nasal irritation

Mild burning or congestion (transient)

—

Sedation

None — distinct from benzodiazepinesMedvedev 2007

—

Dependence / withdrawal

None reported in clinical useZaderej 2014

—

Cognitive impairment

None — opposite effect (enhancement)

—

Allergic reaction

Rare hypersensitivity

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid — insufficient data

ContraindicatedWEGOVY (semaglutide) injection 2021

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

Selank

·Active autoimmune disease (theoretical via immunomodulation)

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

Selank

Semaglutide

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Administration

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Timing

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Storage

Refrigerate after reconstitution; ≤30 days. Light-protected.

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Caveat

Avoid co-administration with strong sedatives or other anxiolytics initially.

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

Selank

— no documented stacks

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)